相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验数据
暂无批准数据
- The UK cardiovascular clinical trials market is forecast to grow from USD 507.8 million in 2025 to USD 892.2 million by 2033, reflecting a compound annual growth rate of 7.6%. - The NHS digital infrastructure encompassing approximately 67 million patient records is a key enabler for participant recruitment and real-world evidence generation in cardiovascular trials. - Approximately 7 million people in England live with cardiovascular conditions, with cardiovascular diseases accounting for about 26% of annual deaths, underscoring the urgent need for new interventions. - Novo Nordisk's January 2026 announcement to extend cardiovascular outcome studies in the UK highlights growing industry investment in obesity-related cardiovascular risk mitigation.
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.
- The global clinical trials support service market is projected to grow from $25.2 billion in 2023 to $47.1 billion by 2032, representing a 7.22% CAGR driven by increasing trial complexity and R&D investments. - Pharmaceutical companies are increasingly outsourcing clinical trials to specialized CROs, with studies showing outsourcing can reduce Phase III trial costs by up to 41% compared to in-house execution. - Patient-centric approaches are reshaping the clinical trials landscape, with diversity in trial participation rising from 20% in 2019 to 35% in 2022, potentially accelerating drug time-to-market by six months.
